HLA Molecular Products
XM-ONE® provides additional information compared to the currently used lymphocyte crossmatch tests and therefore improves the basis for risk assessment prior to transplantation.
XM-ONE® Proficiency Testing Program
Accuracy and standardization of crossmatch results between different centers are essential in organ transplantation. The XM-ONE® proficiency testing (PT) program serves as an important function in accomplishing this goal. The PT program for XM-ONE® is approved by The American Society for Histocompatibility and Immunogenetics (ASHI).
XM-ONE® Multicenter study
The study showed that the XM-ONE® test can detect an antibody population not possible to detect with lymphocyte crossmatch tests that is strongly associated with rejection episodes and reduced kidney function after transplantation. Thus the XM-ONE® test can identify patients at risk of antibody-mediated rejections.